Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Migraine

Zavegepant for the acute treatment of migraine: look before leaping

Nature Reviews Neurology volume 19, pages 329–330 (2023)Cite this article

Subjects

The armamentarium of acute medications for migraine is set to expand further with the results of a phase III trial, in which intranasal administration of zavegepant was superior to placebo in treating a single migraine attack. The therapeutic benefits were modest, however, and so more work is needed to address unmet treatment needs.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Ashina, M. Migraine. N. Engl. J. Med. 383, 1866–1876 (2020).

    Article  CAS  PubMed  Google Scholar 

  2. Eigenbrodt, A. K. et al. Diagnosis and management of migraine in ten steps. Nat. Rev. Neurol. 17, 501–514 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  3. Lipton, R. B., Hamelsky, S. W. & Dayno, J. M. What do patients with migraine want from acute migraine treatment? Headache 42 (Suppl. 1), 3–9 (2002).

    Article  PubMed  Google Scholar 

  4. Ashina, M. et al. Migraine: integrated approaches to clinical management and emerging treatments. Lancet 397, 1505–1518 (2021).

    Article  PubMed  Google Scholar 

  5. Croop, R. et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet 397, 51–60 (2021).

    Article  CAS  PubMed  Google Scholar 

  6. Lipton, R. B. et al. Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial. Lancet Neurol. 22, 209–217 (2023).

    Article  CAS  PubMed  Google Scholar 

  7. Croop, R. et al. Zavegepant nasal spray for the acute treatment of migraine: a phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial. Headache 62, 1153–1163 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  8. Derry, S. & Moore, R. A. Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst. Rev. 2013, CD008040 (2013).

  9. Derry, C. J., Derry, S. & Moore, R. A. Sumatriptan (all routes of administration) for acute migraine attacks in adults — overview of Cochrane reviews. Cochrane Database Syst. Rev. 2014, CD009108 (2014).

  10. Bird, S., Derry, S. & Moore, R. A. Zolmitriptan for acute migraine attacks in adults. Cochrane Database Syst. Rev. 2014, CD008616 (2014).

Download references

Author information

Authors and Affiliations

  1. Harvard Medical School, Boston, MA, USA

    Håkan Ashina

  2. Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA

    Håkan Ashina

  3. Department of Neurology, Danish Headache Center, Copenhagen University Hospital–Rigshospitalet, Copenhagen, Denmark

    Håkan Ashina & Peer Tfelt-Hansen

  4. Department of Brain and Spinal Cord Injury, Copenhagen University Hospital–Rigshospitalet, Copenhagen, Denmark

    Håkan Ashina

  5. Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

    Håkan Ashina

Authors
  1. Håkan Ashina
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peer Tfelt-Hansen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Håkan Ashina.

Ethics declarations

Competing interests

H.A. reports personal fees from Teva, outside of the submitted work. P.T.-H. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ashina, H., Tfelt-Hansen, P. Zavegepant for the acute treatment of migraine: look before leaping. Nat Rev Neurol 19, 329–330 (2023). https://doi.org/10.1038/s41582-023-00803-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41582-023-00803-4

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing